Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease

doi:10.1097/HJH.0000000000002866

CORC > 自动化研究所 > 中国科学院自动化研究所 > 复杂系统管理与控制国家重点实验室 > 互联网大数据与安全信息学研究中心

	Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease
	Tse, Gary 1; Zhou, Jiandong 2; Lee, Sharen 3; Wong, Wing Tak 4; Li, Xintao 5; Liu, Tong 1; Cao, Zhidong 6; Zeng, Daniel Dajun 6; Wai, Abraham K. C.7; Wong, Ian Chi Kei 8
刊名	JOURNAL OF HYPERTENSION
	2021-08-01
卷号	39 期号:8 页码:1717-1724
关键词	angiotensin receptor blockers angiotensin-converting enzyme inhibitors COVID-19 incidence
ISSN号	0263-6352
DOI	10.1097/HJH.0000000000002866
通讯作者	Cheung, Bernard Man Yung(mycheung@hku.hk) ; Zhang, Qingpeng(qingpeng.zhang@cityu.edu.hk)
英文摘要	Background: Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may be associated with higher susceptibility of COVID-19 infection and adverse outcomes. We compared ACEI/ARB use and COVID-19 positivity in a case-control design, and severity in COVID-19 positive patients. Methods: Consecutive patients who attended Hong Kong's public hospitals or outpatient clinics between 1 January and 28 July 2020 for COVID-19 real time-PCR (RT-PCR) tests were included. Baseline demographics, past comorbidities, laboratory tests and use of different medications were compared between COVID-19 positive and negative patients. Severe endpoints for COVID-19 positive patients were 28-day mortality, need for intensive care admission or intubation. Results: This study included 213 788 patients (COVID-19 positive: n = 2774 patients; negative: n = 211 014). In total, 162 COVID-19 positive patients (5.83%) met the severity outcome. The use of ACEI/ARB was significantly higher amongst cases than controls (n = 156/2774, 5.62 vs. n = 6708/211014, 3.17%; P < 0.0001). Significant univariate predictors of COVID-19 positivity and severe COVID-19 disease were older age, higher Charlson score, comorbidities, use of ACEI/ARB, antidiabetic, lipid-lowering, anticoagulant and antiplatelet drugs and laboratory tests (odds ratio >1, P < 0.05). The relationship between the use of ACEI/ARB and COVID-19 positivity or severe disease remained significant after multivariable adjustment. No significant differences in COVID-19 positivity or disease severity between ACEI and ARB use were observed (P > 0.05). Conclusion: There was a significant relationship between ACEI/ARB use and COVID-19 positivity and severe disease after adjusting for significant confounders.
资助项目	National Natural Science Foundation of China (NSFC)[71972164] ; National Natural Science Foundation of China (NSFC)[72042018] ; Health and Medical Research Fund of the Food and Health Bureau of Hong Kong[16171991] ; Innovation and Technology Fund of Innovation and Technology Commission of Hong Kong[MHP/081/19] ; National Key Research and Development Program of China, Ministry of Science and Technology of China[2019YFE0198600] ; Collaborative Research Fund (CRF) of Research Grants Council of Hong Kong[C7154-20G]
WOS关键词	DIFFERENT IMPACT ; ACE-INHIBITORS ; PROGNOSIS ; ENTRY ; SCORE
WOS研究方向	Cardiovascular System & Cardiology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000671996500027
资助机构	National Natural Science Foundation of China (NSFC) ; Health and Medical Research Fund of the Food and Health Bureau of Hong Kong ; Innovation and Technology Fund of Innovation and Technology Commission of Hong Kong ; National Key Research and Development Program of China, Ministry of Science and Technology of China ; Collaborative Research Fund (CRF) of Research Grants Council of Hong Kong
内容类型	期刊论文
源URL	[http://ir.ia.ac.cn/handle/173211/45289]
专题	自动化研究所_复杂系统管理与控制国家重点实验室_互联网大数据与安全信息学研究中心
通讯作者	Cheung, Bernard Man Yung; Zhang, Qingpeng
作者单位	1.Tianjin Med Univ, Tianjin Key Lab Ion Mol Funct Cardiovasc Dis, Dept Cardiol, Tianjin Inst Cardiol,Second Hosp, Tianjin, Peoples R China 2.City Univ Hong Kong, Sch Data Sci, Hong Kong, Peoples R China 3.Chinese Univ Hong Kong, Lab Cardiovasc Physiol, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China 4.Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Peoples R China 5.Soochow Univ, Dept Cardiol, First Peoples Hosp Changzhou, Affiliated Hosp 3, Changzhou, Jiangsu, Peoples R China 6.Chinese Acad Sci, Inst Automat, Beijing, Peoples R China 7.Univ Hong Kong, Emergency Med Unit, Li Ka Shing Fac Med, Pokfulam, Hong Kong, Peoples R China 8.Univ Hong Kong, Dept Pharmacol & Pharm, Pokfulam, Hong Kong, Peoples R China 9.Univ Hong Kong, Div Clin Pharmacol & Therapeut, Dept Med, Pokfulam, Hong Kong, Peoples R China
推荐引用方式 GB/T 7714	Tse, Gary,Zhou, Jiandong,Lee, Sharen,et al. Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease[J]. JOURNAL OF HYPERTENSION,2021,39(8):1717-1724.
APA	Tse, Gary.,Zhou, Jiandong.,Lee, Sharen.,Wong, Wing Tak.,Li, Xintao.,...&Zhang, Qingpeng.(2021).Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease.JOURNAL OF HYPERTENSION,39(8),1717-1724.
MLA	Tse, Gary,et al."Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease".JOURNAL OF HYPERTENSION 39.8(2021):1717-1724.